Johns Hopkins POC-IT: Point of Care Information Technology [Home]
HIV Guide
 Zambia HIV National Guidelines
 


Introduction  

HIV Counseling and Testing  

Sexually Transmitted Infections (STIs)  

General Principles of Antiretroviral Therapy for Chronic HIV Infection in Adults and Adolescents  

When to Start ARV Therapy for Chronic HIV Infection in Adults and Adolescents  

Initial Regimen for ARV Therapy  

Adherence  

Baseline evaluation and Monitoring  

Calculations: Ideal Body Weight, Body Mass Index and Creatinine Clearance  

ARV Therapy for Individuals with Tuberculosis Co-Infection  

Adverse Effects and Toxicity  

Immune Reconstitution Inflammatory Syndrome (IRIS)  

Changing or Stopping ART  

Treatment Failure  

Stopping ARV Therapy  

Post Exposure Prophylaxis  

Cotrimoxazole Prophylaxis  

WHO Staging in Adults and Adolescents  

Nutrition Care and Support  

Palliative Care in HIV and AIDS  

 Guide Editors
 Editor In Chief
    Joel E. Gallant, MD, MPH

Pharmacology Editor
    Paul Pham, PharmD, BCPS

Zambia Guideline Team
   Peter Mwaba MMed PhD FRCP
   Alywn Mwinga MMed
   Isaac Zulu MMed MPH
   Velepie Mtonga MMed
   Albert Mwango MBChB
   Jabbin Mulwanda MMed FCS
 

 

 

Management>Antiretroviral Therapy>
HIV Guide Home PageEmail this module to a friend

Pregnancy and perinatal transmission (Zambia specific)

Christopher J. Hoffmann, M.D., M.P.H.
08-17-2009

DEFINITION

  • HIV transmission risk to infant is 15-30% during labor & delivery and 15% during breast feeding. Rate of transmission during normal gestation is very low.

CLINICAL RECOMMENDATION

Impact of HIV on Fertility and Pregnancy Outcomes

  • Uncontrolled HIV decreases fertility (by approx. 30%); correlates with VLand disease state
  • Uncontrolled HIV worsens pregnancy outcomes (increased still birth, low birth weight, intrauterine growth retardation, chorioamnionitis) and increases maternal mortality (5-fold increase).
  • Control of HIV restores fertility (unexpected pregnancy occurs on average of 1 year after ART initiation)
  • HIV transmission from mother to child occurs in 15-30% of live births and 15% of breast-fed infants. Risk of HIV during pregnancy, delivery, and breastfeeding is approximately 40% without any interventions for prevention of mother to child transmission (PMTCT).
  • Predictors of transmission: acute HIV infection during pregnancy, higher viral load, genital ulcer disease, active HSV
Impact of Pregnancy on HIV Progression

  • Pregnancy does not increase HIV progression, risk for OIs, or HIV-related survival.
  • Pregnancy-related hemodilution may cause apparent decrease in CD4 count (not CD4 %), esp. in 3rd trimester.
Prevention of Mother to Child Transmission (PMTCT)

  • All pregnant women must be screened for HIV during 1st and 3rd trimesters and consider post-partum to identify new HIV during breast feeding. Also should receive standard antenatal syphilis screening, symptomatic STD screening, supplementation of folate, iron, vitamin A, multivitamins and trace minerals.
  • HIV+ women need HIV care and PMTCT services
  • Use of PMTCT can decrease rate of transmission during labor/delivery and breastfeeding to 1-5% (from 40%).
HAART Agents and Pregnancy

  • EFV is a class D agent; use during 1st trimester may increase risk of neural tube defects. Risk is likely to be low based on US birth registry and African experience. Because neural tube develops during 1st trimester, use after this period is probably safe.
  • Initiate HAART with NVP (if CD4 <250, if >250 high risk of hepatotoxicity with NVP) instead of EFV if pregnancy identified in 1st trimester. If pt already on EFV, switch to NVP, even if CD4 >250. Start with full dose NVP 200 mg twice-daily when switching from EFV (no induction dose needed.)
  • AZT & 3TC have demonstrated safety. ABC & TDF also appear safe..
  • LPV/r: decreased serum concentrations during 3rd trimester, of unclear clinical significance in treatment-naive patients. Consider increasing to 3 tabs (600/150 mg) twice-daily during 3rd trimester, especially for PI experienced patients.
  • d4T + ddI: Do not use because of increased risk of pancreatitis and lactic acidosis.
Maternal PMTCT Options

  • ART: Continue ART if on ART. If not on ART, defer initiation until 2nd trimester if mother meets WHO initiation criteria for pregnancy (WHO stage IV; WHO stage III & CD4 <350; CD4<200; Consider if CD4 <350). Recommended regimen for pregnancy: NVP, AZT, 3TC
  • No ART,  HIV identified early in pregnancy: AZT (300 mg PO twice-daily) starting at 28 wks + AZT 600 mg at onset of labor + single dose (sd)-NVP 200 mg at onset of labor. Post-partum: AZT 300 mg twice-daily + 3TC 150 mg twice-daily x 7-14 days (can also use TDF 300 mg + 3TC 300 mg once-daily x 7-14 days)
  • No ART during pregnancy: sd-NVP 200 mg at onset of labor followed by AZT 300 mg twice-daily + 3TC 150 mg twice-daily for 7-14 days
Post-Natal Options to Reduce Transmission

  • HAART for mother: fully suppressive HAART prevents transmission via breast milk to the infant
  • Post-partum: Infant regimen is NVP 2 mg/kg (or 6 mg) immediately after birth + AZT 4 mg/kg twice daily x 7-42 days.
  • If breast feeding: consider NVP (2 mg/kg daily or 5 mg daily) x 6-24 wks (not yet part of WHO guidelines).
  • If breast feeding: Exclusive breast feeding may reduce transmission vs. mixed feeding (mixed evidence). High risk of transmission with either exclusive or mixed if no maternal HAART or infant ART prophylaxis.
  • WHO recommends exclusive replacement feeding (formula) when acceptable, feasible, affordable, sustainable, and safe. However, replacement feeding not recommended for public health approach based on Botswana study in which exclusive replacement feeding increased diarrheal illness and mortality.
  • HIV-negative mothers can become infected during post-natal period. HIV testing and counseling is important if mother is breast feeding.
Single Dose (sd)- NVP and Resistance

  • Following sd-NVP, resistance to NVP detectable among 20-70% of mothers and 30-80% of infected infants.
  • Resistance can be reduced if mother takes AZT+3TC (or TDF+FTC) 1-2 weeks post-partum or if full HAART used during the antenatal period and continued post-partum
  • When NVP resistance detectable following sd-NVP, poorer response to NVP or EFV-containing ART if ART started <6 months after receiving sd-NVP. Improved responses with longer intervals between sd-NVP and ART, but durability of response unknown.
  • For mothers, ART containing NVP or EFV MUST be delayed >6 months after a mother has received sd-NVP.
  • For infants, impact of detectable NVP resistance unclear, but probably compromises NVP or EFV-based ART.
Cotrimoxazole Prophylaxis

  • Infants at risk for MTCT benefit from cotrimoxazole therapy until they are proven HIV-uninfected or CD4 % >25%.
  • Consider starting cotrimoxazole 4-6 wks post-partum in infant. Dose: <6 months, SMX/TMP 100/20mg daily; 6 months - 5 yrs, SMX/TMP 200/40 mg daily.
Sulfadoxine-Pyrimethamine Intermittent Prophylaxis during Pregnancy

  • Malaria risk increased 3-fold by HIV during pregnancy. In addition, HIV reduces effectiveness of WHO recommended 2-dose intermittent preventive treatment during pregnancy with sulfadoxine + pyrimethamine.
  • A more effective regimen for preventing malaria parasitemia during pregnancy is monthly sulfadoxine 1500 mg + pyrimethamine 75 mg
  • Cotrimoxazole also effective for preventing malaria, but not as well studied in pregnancy as sulfadoxine-pyrimethamine.
HIV Testing of Infants

  • Maternal antibodies can remain detectable in infants >1 year post-partum.
  • Antibody testing is only interpretable >15-18 mos post-partum. Earlier testing for infection requires nucleic acid testing (PCR to detect HIV RNA or DNA).
  • If only antibody tests available, testing should be delayed until 18 mos of age.
  • Clinical Dx not sensitive for HIV, as many HIV+ infants remain healthy for 1st year of life. (IMCI clinical Dx guidelines: any 3 of the following: recurrent pneumonia, oral thrush, present or past ear discharge, persistent diarrhea, very low weight, enlarged lymph nodes, parotid enlargement).

OTHER INFORMATION

  • Major current limitation with PMTCT is delivery of services. Current factors limiting delivery are lack of participation by mothers due to stigma of HIV testing and social pressures, availability of testing services, home birthing, and failure to ingest supplied sd-NVP tablet.

REFERENCES

REFERENCED WITHIN THIS GUIDE


 
Diagnosis
 


Complications of Therapy


Malignancies


Miscellaneous


Opportunistic Infections


Organ System

Drugs
 


Antimicrobial Agents


Antiretrovirals


Miscellaneous

Guidelines
 


Zambia HIV National Guidelines

Management
 


Antiretroviral Therapy


Laboratory Testing


Miscellaneous

Pathogens
 


Bacteria


Fungi


Parasites


Viruses

View All Modules
 
Index
 
 
Contacts    Help    Copyright    Acknowledgments    Abbreviations